
Coordinator of the Biochemistry and Structural biology unit @IEOufficiale | @Fornerislab @DBB_unipv @Unipv and @GSK @gsk_it alumnus | views are my own
Joined June 2021
- Tweets228
- Following642
- Followers270
- Likes687
Pinned Tweet
Super happy to share the final shape of our work describing the molecular #structure and #enzymatic mechanism of human #collagen #galactosyltransferase #GLT25D1 published in
@natcomms . Want to know how collagen becomes sweet? read the 🧵 below!
Excited to share our @NaturePortfolio Nature Communications #paper describing the molecular structure and biochemical features of human #collagen #galactosyltransferase GLT25D1/COLGALT1. @unipv @AIRC_it @ArmeniseHarvard
nature.com/articles/s41467-0…
1
5
165
Luigi Scietti retweeted
Cool!
Run an MD simulation of any protein in the AlphaFold Protein Structure Database using AF-CALVADOS
Thanks to Sören von Bülow, AF-CALVADOS is now on Colab
colab.research.google.com/gi…
Luigi Scietti retweeted
Built a tool for myself to easily trim/view/search/download/renumber protein structures for binder design tasks (even on the phone!)
wanted to share in case its helpful to anyone else
seq.design
Luigi Scietti retweeted
I am Open-Sourcing PyMolAI!
Meet PyMolAI, an AI agent that can talk to your protein structures.
Built on top of PyMOL, PyMolAI lets you interact with your structures in plain language. Whether you're:
- Analyzing protein structures
- Aligning complexes
- Creating publication-ready figures
- Or running design workflows
PyMolAI interprets your request, executes the necessary PyMOL commands, and manages the workflow for you.
It integrates with @OpenBioAI APIs, giving you access to tools like Boltz, ProteinMPNN, and BoltzGen — directly from your PyMOL session.
It has local chat history with session syncing, so you can pick up exactly where you left off.
Luigi Scietti retweeted
I recorded ~8h introducing the main algorithms for protein design: from classical approaches to protein language models, ESMFold, MPNN, diffusion models, and more :)
youtu.be/wKUYtAt87d4This
Slides
drive.google.com/file/d/1EPL…
English is available only via auto-translated subtitles
🧵1/3 I created this free 37-hour course, distributed across 10 lectures, to introduce AI-based protein design. For more information about the course and its specific topics, please visit the official course page:
miangoaren.github.io/teachin…
Luigi Scietti retweeted
Amazing open resource for diverse binder kinetics! We released a lot of our BindCraft binders that were not tested experimentally in the original study! Releasing consistent data like this will help the community to grow!
Today we’re releasing real-world experimental data for over 1000 novel AI-designed proteins on our new platform @proteinbase!
Luigi Scietti retweeted
Over the past week, @arcinstitute published three new discoveries that I’m very proud of.
• The world's first functional AI-generated genomes. Using Evo 2 (the largest biology ML model ever trained, which Arc released in partnership with @nvidia in February), Arc scientists took advantage of the fact that Evo 2 is a generative model to produce completely new sequences for complete phage genomes. That is, they used AI to produce wholly new, never-before-seen-by-nature genomes. They experimentally synthesized these genomes and showed that these AI-generated phages actually work, killing E. coli bacteria with high efficacy.
• Germinal, an AI system for creating new antibodies. Antibody design is one of the great problems of medical biology given their obvious importance and usefulness for creating therapeutics. (Antibodies are tiny particles that help the immune system identify pathogens and other harmful intruders. See also the recent Works in Progress article on this topic: [1].) Today, designing effective antibodies is very expensive and slow. Germinal is a cheap and fast way to produce drug candidates, with success rates of up to 22%. This means that one can go from having to screen thousands of candidates in the lab to screening perhaps a few dozen. It's early, but I suspect that better methods for designing antibodies will be a very big deal for disease treatment in the coming years.
• Today, we published a paper showing that “bridge editing”, which Arc scientists first introduced last year, can make precise edits in human cells that are up to 1 million base pairs long, and without relying on intrinsically unpredictable cellular repair machinery (which CRISPR requires, often leading to editing mistakes). They showed that it’s possible to use this editing to cut out the DNA repeats that cause Friedreich’s ataxia (a neurological disease), an approach which should also be relevant to Huntington’s and other similar disorders. One particularly cool thing about it is that it’s possible to specify every nucleotide within the extended editing window, meaning that recursive bridge edits could potentially be a powerful way to reprogram even biological traits that are caused by many genetic mutations. (Genetic therapies today target single mutations.)
Arc is pretty new. Its doors opened in mid 2022, and it's now 300 people. I’m excited about these discoveries because they show that a number of our hopes in starting Arc are starting to pay off:
• AI/ML and computation are at the center of all three. That is obviously true for the first two, but the mobile genetic element behind bridge editing was also discovered as a result of a complex computational search. One of our premises in starting Arc was the belief that the intersection of software/AI and experimental wet lab biology should enable great things. (And besides requiring great computational work, all three of these also required strong wet lab work, tightly coordinated under a single physical roof.)
• We’ve been toying with the idea that a handful of technologies are enabling a new kind of “Turing loop” in biology: sequencing advances (including single-cell sequencing) give us new ways to read; transformers and AI gives us new ways to think; and functional genomics (such as bridge editing) give us new ways to ways to write. This trio of discoveries span each part of this loop, and we’re hopeful that there’ll be compounding returns in improving each part.
• Arc is a non-profit, which we hoped would make collaborating with others easier, since we can avoid worries about financial return. This is indeed proving important, and all three of these projects involved close partnership with others. Germinal was done in partnership with @SynBioGaoLab at Stanford; Evo 2 was trained in partnership with Nvidia. Bridge editing was jointly published with a structure from the @HNisimasu Lab at the University of Tokyo. Arc tries to make its discoveries useful (see the Evo 2 Designer[2]) for others, and the code behind the computational projects is open source, hopefully making it easy for others to spot new opportunities for collaboration and partnership in the future. Most of all, Arc itself is an ongoing collaboration with @UCSF, @UCBerkeley, and @Stanford.
• With Arc, we wanted to enable better bottom-up and top-down work. With the fully flexible, no-strings-attached funding that we provide to investigators, we want to enable completely unexpected discoveries and avenues of investigation. With our institute initiatives (around creating a virtual cell and curing Alzheimer’s), we want to bring to bear a scale and level of coordination that’s usually difficult in basic science. Germinal is a “surprise” discovery that didn’t involve top-down coordination, whereas Evo 2 is the result of ambitious high-level planning and funding.
• Humanity has never cured a complex disease (a category that includes most neurodegenerative diseases, most cancers, and most autoimmune diseases), and my hope is that Arc can help change this. It’s also clear that AI will revolutionize biology, and I hope that Arc can effectively aggregate the ingredients needed to fully capitalize on its promise. I’m biased, but I think some of the coolest biology in the world is currently being done at Arc. (They’re always hiring if you’re interested.)
While I’m a cofounder of Arc, I spend almost all my time on Stripe, where we spend our time building economic infrastructure for the internet. All credit for Arc’s progress should go to the remarkable scientists and staff who’ve made Arc their home or who’ve chosen to collaborate with us. (You can read more about these particular discoveries in these threads: [3], [4], [5].) I’m also very grateful to the amazing Stripe employees who’ve built the company that makes Arc’s ongoing work possible, and to the millions of customers who’ve chosen to partner with Stripe. John and I feel fortunate to be able to support Arc’s work to the extent that we do.
Maybe this is reading too much into it, but I sometimes feel that there’s a commonality between @arcinstitute and @stripe. Both biology and economic infrastructure involve reasoning about complex systems with many levels of emergent effects, and in both cases building the right tools can have almost unboundedly large benefits. Even though progress in both tends to take a long time, it also feels like the next five years in both will be some of the most interesting in living memory.
(If economic infrastructure is your jam, we have a whole slew of fantastic announcements coming up at Stripe Tour in New York next week. Tune in!)
Luigi Scietti retweeted
🔬 Fold proteomes privately, no queues, no bottlenecks
Bring protein structure prediction to your desktop. Powered by the GB10 Grace Blackwell Superchip, our new NVIDIA DGX Spark will deliver:
⚡ 1 petaFLOP of AI performance
🧠 128 GB coherent unified system memory
It’s more than a workstation - it’s a personal AI supercomputer for digital biology.
Get ready to #SparkSomethingBig.
Luigi Scietti retweeted
How are RNAs sorted for export vs. degradation in the nucleus? In collaboration with @torbenheick’s lab we (@plaschka_lab and Julius Brennecke’s lab) discovered a direct mechanistic link between the export and decay machineries: biorxiv.org/content/10.1101/… (1/x)
Luigi Scietti retweeted
Researchers have developed a #DeepLearning system called BioEmu that rapidly generates diverse protein conformations, enabling fast, accurate insights into protein flexibility and function.
Learn more this week in Science: scim.ag/41rCpxZ
Luigi Scietti retweeted
🎉New preprint!🎉 Extremely excited to share CryoBoltz❄️⚡️, led by superstar @rishwanth_raghu!
We develop a multiscale guidance recipe to steer structure prediction models (e.g. AlphaFold3 / Boltz-1) towards experimental cryo-EM density maps, including heterogeneous, low-resolution data!
CryoBoltz ❄️⚡️bridges protein structure prediction and cryo-EM structure determination. We believe this opens up exciting directions for data-guided structure prediction and atomic modeling of dynamic molecules.
Check out @rishwanth_raghu's thread below for more details! So fun to work with the dream team @rishwanth_raghu @axlevy0 and @GordonWetzstein on this paper.
Finally, this work was made possible by the openly available Boltz-1 repo and the AlphaFold3 release. Excited to see the continuing developments with Boltz-2 and beyond!
Excited to present CryoBoltz ❄️⚡, a multiscale guidance approach for steering AlphaFold3/Boltz-1 to sample structures that are consistent with experimental cryo-EM density maps. 🧵1/7
arxiv.org/abs/2506.04490
Joint work with @axlevy0 @GordonWetzstein & @ZhongingAlong!
Luigi Scietti retweeted
Building atomic models to cryo-EM maps of huge molecules is intimidating: crowded, uncertain copy numbers, variable resolution ...
@theliulab and team show how cross-linking MS can be used to build novel models of unknown complexes, like a giant virus❄️ ❄️biorxiv.org/content/10.1101/…
Luigi Scietti retweeted
The ChimeraX 1.10 release candidate and daily builds can predict small complexes of proteins, nucleic acids and small molecules using Boltz on your Mac, Windows or Linux computer. rbvi.ucsf.edu/chimerax/data/…
Amazing #cryoEM structures and incredible community here at @CNIOStopCancer for the “machines acting on DNA and RNA” congress!
This was a massive work from
@fornerislab fellows to which I contributed when I was Postdoc, and great #teamwork with Giorgio Colombo lab,@iacobucciCla and @AlbertaPinnola lab
I also had fun in making gummy GLT25D1 making #notthecover using #blender


























